The ASCO Post

🖥️ #ASCOAI: This week in #AI and #oncology:

🔹@AmerMedicalAssn framework on agentic AI
🔹@FDA breakthrough device for deep learning oral cytology test
🔹ALLIANCE trial on clinicians using LLMs for patient care from #ESMO26

📽️ Watch the full news brief: ascoai.org/videos/weekly-…

🩻Shorter-course radiation may reduce AEs in high-risk #BreastCancer.

In HypoMast-IMNI, grade 3 acute skin toxicity occurred in 1.7% of patients with hypofractionated radiotherapy vs 12.2% with conventional treatment.

🔹 Jinli Ma, MD, PhD | @JCO_ASCO

ascopost.com/news/november-…

🚺 Phase 2️⃣ NANT findings show neoadjuvant niraparib induced 63% ORR in patients with HRD+ advanced #OvarianCancer who were unlikely to achieve R0 debulking.

➡️ 80% who went on to surgery achieved R0 resection

▪️Qinglei Gao, MD | @TheLancetOncol

🔗 ascopost.com/news/november-…

🥼#ASCOAI: How will #AI shape the future of #CancerCare?

At the 2026 @ASCO Quality Care Symposium, multidisciplinary experts debated AI's impact on patient trust, clinical decision-making, regulation, and health equity. #ASCOQLTY26

Learn more ➡️ ascoai.org/articles/2026/…

🚹 Five-treatment SBRT remains an effective nonsurgical option for localized #ProstateCancer.

Updated PACE-A results showed high cancer control rates with both SBRT & surgery, while urinary and sexual function outcomes favored SBRT.

🔹@nickva1 | #ASTRO26
ascopost.com/news/november-…